DNA-Damage Test Could Aid Drug Development
News May 18, 2007
In the daunting marathon that leads to successful drugs, promising drug candidates must pass toxicity tests before entering clinical trials. Researchers from Massachusetts Institute of Technology and Whitehead Institute have developed a cell culture test for assessing a compound’s genetic toxicity that may prove dramatically cheaper than existing animal tests. This assay would allow genetic toxicity to be examined far earlier in the drug development process, making it much more efficient.
Like the current FDA-approved test, the new test looks for DNA damage in red blood cells formed in the bone marrow of mice. The precursors to red blood cells are handy for this because such cells normally lose their nucleus during the last stage of red cell formation, and DNA-damaged precursors generate red blood cells containing an easily detected micronucleus consisting of fragments of nuclear DNA.
Unlike the current procedure, which injects the compound into a live mouse, the new assay is a cell-culture system that could allow hundreds or thousands of tests to be performed from the bone marrow of a single mouse, and potentially from human bone marrow.
Joe Shuga, the graduate student in chemical engineering who developed the assay, is in the unusual position of being a graduate student in three labs, those of Professors Linda Griffith, Harvey Lodish (a Whitehead Member) and Leona Samson. “We’re all faculty in the Biological Engineering department, and collaborative projects like this are what the department was intended to do,” comments Griffith, senior author on a paper to be published online in the Proceedings of the National Academy of Science the week of May 14.
“This research is the first stage in a new type of clinical drug toxicity test,” says Lodish.
“This is an example of taking fundamental lab science and doing something useful with it,” says Lodish, whose lab has extensively studied the process by which red blood cells are generated.
This work was funded by the Cambridge-MIT Institute, Amgen, the National Institutes of Health, and the National Science Foundation.